As we previously reported, Biogen sued Sandoz and Polpharma (“Defendants”) in a BPCIA litigation related to Defendants’ natalizumab biosimilar. On October 19, 2022, Biogen filed a Motion for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback